Soyoko Morimoto

1.1k citations

37 papers · 388 indexed · h-index 13

Co-authors: Haruo Sugiyama Akihiro Tsuboi Fumihiro Fujiki Hiroko Nakajima Yusuke Oji Yoshitaka Oka Naoki Hosen Sumiyuki Nishida
Topics: Renal and related cancers (20 papers)Immunotherapy and Immune Responses (19 papers)CAR-T cell therapy research (17 papers)
Cited by: Immunology Oncology Genetics
Journals: Journal of Clinical Oncology Blood PLoS ONE
Partner nations: Japan Australia United States

In The Last Decade

Soyoko Morimoto

35 papers receiving 384 citations

Peers

Countries citing papers authored by Soyoko Morimoto

Since Specialization

Citations

This map shows the geographic impact of Soyoko Morimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Soyoko Morimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Soyoko Morimoto more than expected).

Fields of papers citing papers by Soyoko Morimoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Soyoko Morimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Soyoko Morimoto. The network helps show where Soyoko Morimoto may publish in the future.

Co-authorship network of co-authors of Soyoko Morimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Soyoko Morimoto. A scholar is included among the top collaborators of Soyoko Morimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Soyoko Morimoto. Soyoko Morimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia 2023 ·BMC Cancer ·(unknown),Yoshiko Hashii,Hiroko Nakajima,Fumihiro Fujiki,Soyoko Morimoto,Jun Nakata,Toshiro Shirakawa,Takane Katayama,Akihiro Tsuboi,Keiichi Ozono	5
2	Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs 2023 ·Cancer Immunology Immunotherapy ·Fumihiro Fujiki,Soyoko Morimoto,(unknown),(unknown),(unknown),(unknown),Kento Inoue,(unknown),Hiroko Nakajima,Jun Nakata,Sumiyuki Nishida,Akihiro Tsuboi,Yoshitaka Oka,Yusuke Oji,Shinji Sogo,Haruo Sugiyama	1
3	An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia 2022 ·Cancer Immunology Immunotherapy ·Natsuki Nakagawa,Yoshiko Hashii,Hisako Kayama,Ryu Okumura,Hiroko Nakajima,(unknown),Soyoko Morimoto,Fumihiro Fujiki,Jun Nakata,Toshiro Shirakawa,Takane Katayama,Kiyoshi Takeda,Akihiro Tsuboi,Keiichi Ozono	14
4	T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy 2022 ·Frontiers in Immunology ·Fumihiro Fujiki,Soyoko Morimoto,(unknown),(unknown),(unknown),(unknown),(unknown),Ayako Isotani,Masahito Ikawa,Sumiyuki Nishida,Hiroko Nakajima,Akihiro Tsuboi,Yoshitaka Oka,Jun Nakata,Naoki Hosen,Atsushi Kumanogoh,Yusuke Oji,Haruo Sugiyama	8
5	Imaging Assessment of Tumor Response in the Era of Immunotherapy 2021 ·Diagnostics ·Jun Nakata,Kayako Isohashi,Yoshitaka Oka,Hiroko Nakajima,Soyoko Morimoto,Fumihiro Fujiki,Yusuke Oji,Akihiro Tsuboi,Atsushi Kumanogoh,Naoya Hashimoto,Jun Hatazawa,Haruo Sugiyama	7
6	Identification of mouse helper epitopes for WT1-specific CD4+ T cells 2021 ·Cancer Immunology Immunotherapy ·Hiroko Nakajima,Jun Nakata,(unknown),(unknown),(unknown),Keiko Udaka,Fumihiro Fujiki,Soyoko Morimoto,Kana Hasegawa,Naoki Hosen,Yoshiko Hashii,Sumiyuki Nishida,Akihiro Tsuboi,Yoshitaka Oka,Yusuke Oji,Shinji Sogo,Haruo Sugiyama	6
7	Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides 2020 ·Cancer Immunology Immunotherapy ·Fumihiro Fujiki,Akihiro Tsuboi,Soyoko Morimoto,Naoya Hashimoto,(unknown),Hiroko Nakajima,Jun Nakata,Sumiyuki Nishida,Kana Hasegawa,Naoki Hosen,Yoshitaka Oka,Yusuke Oji,Shinji Sogo,Haruo Sugiyama	7
8	A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma 2018 ·Cancer Immunology Immunotherapy ·Akihiro Tsuboi,Naoya Hashimoto,Fumihiro Fujiki,Soyoko Morimoto,Naoki Kagawa,Hiroko Nakajima,Naoki Hosen,Sumiyuki Nishida,Jun Nakata,Satoshi Morita,Junichi Sakamoto,Yusuke Oji,Yoshitaka Oka,Haruo Sugiyama	43
9	Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides 2018 ·Oncotarget ·Jun Nakata,Hiroko Nakajima,(unknown),(unknown),Soyoko Morimoto,Fumihiro Fujiki,Daisuke Motooka,Daisuke Okuzaki,Kana Hasegawa,Naoki Hosen,Akihiro Tsuboi,Yoshitaka Oka,Atsushi Kumanogoh,Yusuke Oji,Haruo Sugiyama	14
10	A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches 2018 ·Oncotarget ·(unknown),(unknown),Katrijn Broos,Fumihiro Fujiki,Diana Campillo-Davó,Hans De Reu,Soyoko Morimoto,Quentin Lecocq,Marleen Keyaerts,Zwi Berneman,Haruo Sugiyama,Viggo Van Tendeloo,Karine Breckpot,Eva Lion	18
11	An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells 2016 ·Journal of Immunotherapy ·Kenta Kondo,Fumihiro Fujiki,Hiroko Nakajima,(unknown),Soyoko Morimoto,Naoya Tatsumi,Sumiyuki Nishida,Jun Nakata,Yoshitaka Oka,Akihiro Tsuboi,Naoki Hosen,Yusuke Oji,Haruo Sugiyama	2
12	Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response 2015 ·Cancer Immunology Immunotherapy ·Naoya Hashimoto,Akihiro Tsuboi,Naoki Kagawa,Yasuyoshi Chiba,Shuichi Izumoto,Manabu Kinoshita,Noriyuki Kijima,Yoshitaka Oka,Soyoko Morimoto,Hiroko Nakajima,Satoshi Morita,Junichi Sakamoto,Sumiyuki Nishida,Naoki Hosen,Yusuke Oji,Norio Arita,Toshiki Yoshimine,Haruo Sugiyama	34
13	An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells 2015 ·PLoS ONE ·Kana Hasegawa,Satomi Tanaka,Fumihiro Fujiki,Soyoko Morimoto,Hiroko Nakajima,Naoya Tatsumi,Jun Nakata,S Takashima,Sumiyuki Nishida,Akihiro Tsuboi,Yoshitaka Oka,Yusuke Oji,Atsushi Kumanogoh,Haruo Sugiyama,Naoki Hosen	13
14	Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms 2015 ·PLoS ONE ·Naoya Tatsumi,(unknown),Hiroyuki Sakamoto,(unknown),(unknown),(unknown),Mari Fukuda,Akihide Matsumura,Seiji Hayashi,Soyoko Morimoto,Jun Nakata,Fumihiro Fujiki,Sumiyuki Nishida,Hiroko Nakajima,Akihiro Tsuboi,Yoshitaka Oka,Naoki Hosen,Haruo Sugiyama,Yusuke Oji	9
15	Abstract CT218: Wilms′ tumor gene 1 (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer 2014 ·Cancer Research ·Shigeo Koido,Sumiyuki Nishida,Sadamu Homma,Yutaka Takeda,Hideo Komita,Satoshi Morita,Toshinori Ito,Soyoko Morimoto,Yoshitaka Oka,Satoru Yanagisawa,Yoichi Toyama,Masahiro Ikegami,Hiroaki Nagano,Toshifumi Ohkusa,Hisao Tajiri,Haruo Sugiyama	2
16	In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity 2013 ·Leukemia ·Jun Nakata,(unknown),Atsushi Okumura,(unknown),Hidenori Kinoshita,(unknown),Kana Hasegawa,Soyoko Morimoto,Fumihiro Fujiki,N Tatsumi,Hiroko Nakajima,Yoshiki Nakae,Sumiyuki Nishida,Akihiro Tsuboi,Yusuke Oji,Yoshitaka Oka,Haruo Sugiyama,Atsushi Kumanogoh,Naoki Hosen	8
17	HLA-DPB105 2013 ·Journal of Immunotherapy* ·Yu‐Hung Lin,Fumihiro Fujiki,(unknown),Yoshitaka Oka,Akihiro Tsuboi,(unknown),(unknown),Hiroko Nakajima,Naoya Tatsumi,Soyoko Morimoto,(unknown),Sho Tachino,Naoki Hosen,Sumiyuki Nishida,Yusuke Oji,Atsushi Kumanogoh,Haruo Sugiyama	16
18	Functional human Th17 clones with WT1-specific helper activity 2012 ·Cancer Immunology Immunotherapy ·Sho Tachino,Fumihiro Fujiki,Yoshitaka Oka,Akihiro Tsuboi,Soyoko Morimoto,Yu‐Hung Lin,(unknown),Kenta Kondo,Hiroko Nakajima,Sumiyuki Nishida,Naoki Hosen,Yusuke Oji,Atsushi Kumanogoh,Haruo Sugiyama	1
19	Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration 2011 ·Vaccine ·Hiroko Nakajima,Yoshitaka Oka,Akihiro Tsuboi,Naoya Tatsumi,Yumiko Yamamoto,Fumihiro Fujiki,Zheyu Li,(unknown),Soyoko Morimoto,Naoki Hosen,Toshiaki Shirakata,Sumiyuki Nishida,Ichiro Kawase,Yoshitaka Isaka,Yusuke Oji,Haruo Sugiyama	16
20	Osteoclast-like cells express receptor activity modifying protein 2: application of laser capture microdissection 2005 ·Journal of Molecular Endocrinology ·Miki Nakamura,Soyoko Morimoto,Qifeng Yang,Tadakazu Hisamatsu,Nobuo Hanai,Yoshio Nakamura,Ichiro Mori,Kennichi Kakudo	11

About Soyoko Morimoto

Soyoko Morimoto is a scholar working on Immunology, Oncology and Molecular Biology, having authored 37 papers that have together received 388 indexed citations. Recurring topics across this work include Renal and related cancers (20 papers), Immunotherapy and Immune Responses (19 papers) and CAR-T cell therapy research (17 papers). The work is most often cited by research in Immunology (209 citations), Oncology (188 citations) and Genetics (47 citations). Soyoko Morimoto has collaborated with scholars based in Japan, Australia and United States. Frequent co-authors include Haruo Sugiyama, Akihiro Tsuboi, Fumihiro Fujiki, Hiroko Nakajima, Yusuke Oji, Yoshitaka Oka, Naoki Hosen, Sumiyuki Nishida, Jun Nakata and Atsushi Kumanogoh. Their work appears in journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact